Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine.

Posted by on in 2016
  • Font size: Larger Smaller
  • Hits: 772
  • Print

Nothaft H1,2Davis B3Lock YY3Perez-Munoz ME4Vinogradov E5Walter J1,4Coros C3Szymanski CM1,22016. Sci Rep. 6:26511. doi: 10.1038/srep26511.

Department of Biological Sciences, University of Alberta, Edmonton, Canada.
Alberta Glycomics Centre, University of Alberta, Edmonton, Canada.
Delta Genomics, Edmonton, Canada.
Department of Agricultural, Food &Nutritional Science, University of Alberta, Edmonton, Canada.
Human Health Therapeutics, National Research Council, Ottawa, Canada.


Campylobacter jejuni is a predominant cause of human gastroenteritis worldwide. Source-attribution studies indicate that chickens are the main reservoir for infection, thus elimination of C. jejuni from poultry would significantly reduce the burden of human disease. We constructed glycoconjugate vaccines combining the conserved C. jejuni N-glycan with a protein carrier, GlycoTag, or fused to the Escherichia coli lipopolysaccharide-core. Vaccination of chickens with the protein-based or E. coli-displayed glycoconjugate showed up to 10-log reduction in C. jejuni colonization and induced N-glycan-specific IgY responses. Moreover, the live E. coli vaccine was cleared prior to C. jejuni challenge and no selection for resistant campylobacter variants was observed. Analyses of the chicken gut communities revealed that the live vaccine did not alter the composition or complexity of the microbiome, thus representing an effective and low-cost strategy to reduce C. jejuni in chickens and its subsequent entry into the food chain.

Last modified on